|1.||Chick, J: 3 articles (04/2008 - 08/2006)|
|2.||Drolet, Daniel W: 2 articles (12/2008 - 06/2004)|
|3.||Chick, Jon: 2 articles (12/2008 - 08/2005)|
|4.||Valle, J W: 2 articles (04/2008 - 08/2006)|
|5.||Albert, D: 2 articles (08/2007 - 08/2006)|
|6.||Rothenberg, Mace L: 1 article (12/2008)|
|7.||Rowinsky, Eric K: 1 article (12/2008)|
|8.||Papadopoulos, Kyriakos P: 1 article (12/2008)|
|9.||Ricart, Alejandro D: 1 article (12/2008)|
|10.||Syed, Samira: 1 article (12/2008)|
08/01/2005 - "This phase I study was done to establish the safety, tolerability, maximum tolerated dose, recommended dose, and pharmacokinetics of OSI-7904L in patients with advanced solid tumors refractory to standard therapy. "
06/01/2004 - "These data clearly demonstrated that in mice, OSI-7904L has an increased plasma residence time as well as increased tissue and tumor exposure compared with OSI-7904, thus resulting in increased potency and toxicity. "
06/01/2004 - "Furthermore, OSI-7904L could be administered less frequently than OSI-7904 although still generating greater tumor growth inhibition. "
08/01/2007 - "This randomised study was designed to evaluate the effectiveness of a new liposomal thymidylate synthase inhibitor (TSI), OSI-7904L, in parallel with a modified de Gramont regimen of 5-FU/LV in patients with advanced biliary cancer. "
08/01/2005 - "Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors."
|2.||Colorectal Neoplasms (Colorectal Cancer)
04/01/2008 - "This phase I study evaluated the safety, tolerability and pharmacokinetics (PK) of OSI-7904L administered in combination with oxaliplatin every 21 days in patients with advanced colorectal carcinoma. "
04/01/2008 - "A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer."
10/01/2006 - "Developments that may improve existing cytotoxic therapy for colorectal cancer (CRC) include alternatives to 5-fluorouracil (5-FU) such as the liposomal Thymidylate Synthase inhibitor OSI-7904L and the multitargeted antifolate pemetrexed. "
08/21/2006 - "Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma."
06/01/2004 - "In a human colon adenocarcinoma xenograft model in mice, OSI-7904L demonstrated superior antitumor efficacy compared with OSI-7904 or 5-fluorouracil. "
08/21/2006 - "A two-stage Simon design was used to evaluate the response rate of OSI-7904L, a liposome encapsulated thymidylate synthase inhibitor, in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA), administered intravenously at 12 mg m(-2) over 30 min every 21 days. "
08/01/2007 - "Patients with previously untreated advanced or metastatic carcinoma of the biliary tract were randomised to receive either OSI-7904L 12 mg/m2 intravenously every 21 days or a modified de Gramont schedule of 5-FU/LV (intravenous l-LV 200 mg/m2, bolus 5-FU 400 mg/m2 and a 46-h infusion of 5-FU 2,400 mg/m2) every 14 days. "
|5.||Biliary Tract Neoplasms (Biliary Tract Cancer)
|2.||Leucovorin (Folinic Acid)
|1.||Heterologous Transplantation (Xenotransplantation)